Ondansetron 8 MG Disintegrating Oral Tablet — RxCUI 312087
RxNorm drug concept · Semantic clinical drug
RxCUI 312087
Semantic clinical drug · SCD
● Current RxNorm concept 65 FDA products
215 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI312087
Official nameOndansetron 8 MG Disintegrating Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped65
Package NDCs mapped215
Reported Medicaid activity (SDUD)6,908,547 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Ondansetron: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Not at all. Ondansetron is approved to prevent nausea and vomiting from cancer chemotherapy, radiation therapy to the abdomen or whole body, and surgery. So you might receive it be...
- What exactly is ondansetron used for — is it just for chemo patients?
- The regular tablet is swallowed like any other pill. The orally disintegrating tablet (ODT) is placed on your tongue and allowed to dissolve — don't chew or swallow it whole. For c...
- How do I take the tablet or the dissolving tablet correctly?
🕸️ Concept Web — How Ondansetron 8 MG Disintegrating Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Ondansetron 8 MG Disintegrating Oral Tablet
RxCUI 312087 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Ondansetron
26225IN
-
Ondansetron
-
Dose forms 8
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Ondansetron Disintegrating Oral Tablet
373149SCDF -
Ondansetron Disintegrating Oral Product
1295332SCDG -
Ondansetron Oral Product
1161033SCDG -
Ondansetron Pill
1161034SCDG -
Disintegrating Oral Tablet
316942DF -
Disintegrating Oral Product
1294713DFG -
Oral Product
1151131DFG -
Pill
1151133DFG
-
Ondansetron Disintegrating Oral Tablet
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Ondansetron 8 MG
328451SCDC
-
Ondansetron 8 MG
Showing up to 8 concepts per family — 10 of 10 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Ondansetron 8 MG
SCDC · 328451 -
Ondansetron Disintegrating Oral Tablet
SCDF · 373149 -
Ondansetron Disintegrating Oral Product
SCDG · 1295332 -
Ondansetron Oral Product
SCDG · 1161033 -
Ondansetron Pill
SCDG · 1161034
📦 FDA Products & Package NDCs
65 products · 215 package NDCs
215 package NDCs map to RxCUI 312087 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 80425-0227-01 | 10 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, UNIT-DOSE (804... | Ondansetron | Advanced Rx Pharmacy of Tennessee, LLC | 2023-01-11 |
| 83980-0012-01 | 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (83980-012-01) | Ondansetron | Ipca Laboratories Limited | 2025-06-19 |
| 83980-0012-10 | 1000 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (83980-012-10... | Ondansetron | Ipca Laboratories Limited | 2025-06-19 |
| 83980-0012-13 | 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (83980-012-13) | Ondansetron | Ipca Laboratories Limited | 2025-06-19 |
| 83980-0012-83 | 3 BLISTER PACK in 1 CARTON (83980-012-83) / 10 TABLET, ORAL... | Ondansetron | Ipca Laboratories Limited | 2025-06-19 |
| 83980-0013-01 | 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (83980-013-01) | Ondansetron | Ipca Laboratories Limited | 2025-06-19 |
| 83980-0013-10 | 1000 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (83980-013-10... | Ondansetron | Ipca Laboratories Limited | 2025-06-19 |
| 83980-0013-13 | 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (83980-013-13) | Ondansetron | Ipca Laboratories Limited | 2025-06-19 |
| 83980-0013-83 | 3 BLISTER PACK in 1 CARTON (83980-013-83) / 10 TABLET, ORAL... | Ondansetron | Ipca Laboratories Limited | 2025-06-19 |
| 85766-0038-04 | 1 BLISTER PACK in 1 CARTON (85766-038-04) / 4 TABLET, ORALL... | Ondansetron | Sportpharm LLC | 2025-08-07 |
| 85766-0038-06 | 1 BLISTER PACK in 1 CARTON (85766-038-06) / 6 TABLET, ORALL... | Ondansetron | Sportpharm LLC | 2025-08-07 |
| 85766-0038-10 | 1 BLISTER PACK in 1 CARTON (85766-038-10) / 10 TABLET, ORAL... | Ondansetron | Sportpharm LLC | 2025-08-07 |
| 85766-0038-20 | 2 BLISTER PACK in 1 CARTON (85766-038-20) / 10 TABLET, ORAL... | Ondansetron | Sportpharm LLC | 2025-08-07 |
| 85766-0038-24 | 24 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (85766-038-24) | Ondansetron | Sportpharm LLC | 2025-10-03 |
| 85766-0038-30 | 3 BLISTER PACK in 1 CARTON (85766-038-30) / 10 TABLET, ORAL... | Ondansetron | Sportpharm LLC | 2025-08-07 |
Observed labelers:
Bryant Ranch Prepack (66) ·
Proficient Rx LP (24) ·
A-S Medication Solutions (16) ·
Aurobindo Pharma Limited (11) ·
Asclemed USA, Inc. (10) ·
Sun Pharmaceutical Industries, Inc. (9)
· +18 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| Q0162 | Ondansetron oral | 31 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.